nebilet comp 5 mg / 25 mg tabletti, kalvopäällysteinen
menarini international operations luxembourg s.a. - nebivololi hydrochloridum,hydrochlorothiazidum - tabletti, kalvopäällysteinen - 5 mg / 25 mg - nebivololi ja tiatsidit
ketesse 12.5 mg rakeet oraaliliuosta varten
menarini international operations luxembourg s.a. - dexketoprofenum trometamolum - rakeet oraaliliuosta varten - 12.5 mg - deksketoprofeeni
enantyum 12.5 mg tabletti, kalvopäällysteinen
laboratorios menarini s.a - dexketoprofenum trometamolum - tabletti, kalvopäällysteinen - 12.5 mg - deksketoprofeeni
enantyum 25 mg tabletti, kalvopäällysteinen
laboratorios menarini s.a - dexketoprofenum trometamolum - tabletti, kalvopäällysteinen - 25 mg - deksketoprofeeni
enantyum 50 mg / 2 ml injektioneste, liuos/infuusiokonsentraatti, liuosta varten
laboratorios menarini s.a - dexketoprofenum trometamolum - injektioneste, liuos/infuusiokonsentraatti, liuosta varten - 50 mg / 2 ml - deksketoprofeeni
espumisan 100 mg/ml tipat, emulsio
berlin-chemie ag - simeticonum - tipat, emulsio - 100 mg/ml - silikonit
enantyum 12.5 mg rakeet oraaliliuosta varten
laboratorios menarini s.a - dexketoprofenum trometamolum - rakeet oraaliliuosta varten - 12.5 mg - deksketoprofeeni
enantyum 25 mg rakeet oraaliliuosta varten
laboratorios menarini s.a - dexketoprofenum trometamolum - rakeet oraaliliuosta varten - 25 mg - deksketoprofeeni
elzonris
stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastiset aineet - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).
nexpovio
stemline therapeutics b.v. - selinexor - multiple myeloma - antineoplastiset aineet - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.